• Shubhayan Sanatani, James E Potts, John H Reed, J Philip Saul, Elizabeth A Stephenson, Karen A Gibbs, Charles C Anderson, Andrew S Mackie, Pamela S Ro, Svjetlana Tisma-Dupanovic, Ronald J Kanter, Anjan S Batra, Anne Fournier, Andrew D Blaufox, Harinder R Singh, Bertrand A Ross, Kenny K Wong, Yaniv Bar-Cohen, Brian W McCrindle, and Susan P Etheridge.
• Division of Pediatric Cardiology, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. ssanatani@cw.bc.ca
• Circ Arrhythm Electrophysiol. 2012 Oct 1;5(5):984-91.

BackgroundSupraventricular tachycardia (SVT) is one of the most common conditions requiring emergent cardiac care in children, yet its management has never been subjected to a randomized controlled clinical trial. The purpose of this study was to compare the efficacy and safety of the 2 most commonly used medications for antiarrhythmic prophylaxis of SVT in infants: digoxin and propranolol.Methods And ResultsThis was a randomized, double-blind, multicenter study of infants <4 months with SVT (atrioventricular reciprocating tachycardia or atrioventricular nodal reentrant tachycardia), excluding Wolff-Parkinson-White, comparing digoxin with propranolol. The primary end point was recurrence of SVT requiring medical intervention. Time to recurrence and adverse events were secondary outcomes. Sixty-one patients completed the study, 27 randomized to digoxin and 34 to propranolol. SVT recurred in 19% of patients on digoxin and 31% of patients on propranolol (P=0.25). No first recurrence occurred after 110 days of treatment. The 6-month recurrence-free status was 79% for patients on digoxin and 67% for patients on propranolol (P=0.34), and there were no first recurrences in either group between 6 and 12 months. There were no deaths and no serious adverse events related to study medication.ConclusionsThere was no difference in SVT recurrence in infants treated with digoxin versus propranolol. The current standard practice may be treating infants longer than required and indicates the need for a placebo-controlled trial. Clinical Trial Registration Information- http://clinicaltrials.gov; NCT-00390546.

21 keywords...

hide…